Peripheral sensory terminal degeneration is linked to sensory fiber hyperexcitability in paclitaxel-induced...

Paclitaxel-induced peripheral neuropathy (PIPN) is the most common dose-limiting side effect of paclitaxel chemotherapy, yet the relationship between structural damage to peripheral nerve terminals and functional impairment of nociceptors has not been directly examined. Here we combined ex vivo skin-nerve electrophysiology with three-dimensional (3D) imaging of fDISCO-cleared glabrous skin to characterize both morphological and functional changes in peripheral sensory terminals following paclitaxel treatment in rats. Five weeks after paclitaxel administration, skin-nerve recordings revealed a marked increase in the proportion of C- and Aδ-fibers exhibiting spontaneous discharge (approximately 2.4- and 2.6-fold increases, respectively) compared to vehicle-treated controls. Paclitaxel also selectively reduced the mechanical activation threshold of C-fibers without affecting Aδ fibers. Three-dimensional reconstruction of PGP9.5-immunolabeled nerve terminals showed that sensory fibers in glabrous skin form a vertically oriented, tree-like architecture. Paclitaxel treatment severely reduced both the terminal branch length and the density of free nerve endings in the epidermis. Strikingly, co-administration of the Kv7 channel activator retigabine prevented both the electrophysiological and morphological alterations induced by paclitaxel. These findings provide direct evidence that peripheral nerve terminal degeneration and hyperexcitability co-occur in PIPN and that Kv7 channel activation can protect against both structural and functional damage.

This study provides the first direct evidence linking intraepidermal sensory terminal degeneration with peripheral sensory fiber hyperexcitability in paclitaxel-induced peripheral neuropathy by combining skin-nerve electrophysiology with three-dimensional imaging of sensory terminals. Paclitaxel induces distal degeneration of intraepidermal sensory terminals, increases spontaneous discharge, and lowers the mechanical activation threshold of C-fibers, demonstrating that structural degeneration and functional abnormalities occur concurrently in the peripheral terminal. Retigabine prevents both structural and functional alterations, supporting peripheral sensory terminals as a therapeutic target for preventing chemotherapy-induced neuropathy.